盐酸替洛利生

盐酸替洛利生

中文名称盐酸替洛利生
中文同义词1-[3-[3-(4-氯苯基)丙氧基]丙基]哌啶盐酸盐;1-[3-[3-(4-氯丙基)丙氧基]丙基]-哌啶盐酸盐;替洛利生盐酸盐;盐酸替洛利生;BF 2649 盐酸盐
英文名称1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride
英文同义词1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidinehydrochloride;BF 2649;Ciproxidine;Pitolisant (hydrochloride);1-[3-[3-(4-Chlorophenyl)propoxy]propyl]piperidine monohydrochloride;Piperidine, 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-, hydrochloride;BF 2649 hydrochloride;Ciproxidine BF2649
CAS号903576-44-3
分子式C17H26ClNO.HCl
分子量332
EINECS号
相关类别Inhibitor
Mol文件903576-44-3.mol
结构式盐酸替洛利生 结构式

盐酸替洛利生 性质

储存条件Desiccate at RT
溶解度DMSO 中≥16.6 mg/mL;水中≥57.4 mg/mL;乙醇中≥94.2 mg/mL
形态固体

盐酸替洛利生 用途与合成方法

盐酸替洛利生是替洛利生的盐酸盐形式,替洛利生是一种选择性组胺H3受体反向激动剂,在欧洲药品管理局(EMA)和美国食品药品监督管理局(FDA)分别获得了孤儿药认定,且被美国FDA认定为突破性治疗药物。
2023年6月30日,琅钰集团宣布中国国家药品监督管理局(NMPA)正式批准盐酸替洛利生片(铧可思®)用于治疗发作性睡病(Narcolepsy)成人患者的日间过度嗜睡(EDS)或猝倒。
盐酸替洛利生片
发作性睡病(Narcolepsy)是全球公认的罕见病,是一种罕见的睡眠/觉醒障碍疾病,通常被认为是终身性疾病,临床上以日间过度嗜睡(excessive daytime sleepiness,EDS)、猝倒(cataplexy)、入睡前幻觉、睡眠瘫痪和夜间睡眠紊乱为主要特征,对患者的生活质量、工作或学习能力、以及身心健康往往造成严重的影响。替洛利生(Pitolisant)由法国Bioprojet研发,是一款first-in-class选择性组胺3(H3)受体拮抗剂/反向激动剂,通过一种全新的作用机制发挥作用,即通过增强组胺能神经元活性,增加大脑中促进觉醒的神经递质组胺的合成和释放,进而提高患者的清醒度和警觉性。该药于2019年8月获FDA批准上市,是第一个也是唯一一个不受美国缉毒局管制的治疗发作性睡病药物。2020年10月,琅铧医药与Bioprojet就Pitolisant膜包衣片(4.45 mg和17.8 mg)达成战略合作和独家授权协议,获得中国的独家开发、注册、商业化和生产权益。2021年,Pitolisant用于发作性睡病成人患者的日间过度嗜睡或猝倒的上市申请获药监局受理。
替洛利生是全球范围内唯一获得发作性睡病适应症,并且同时被美国、欧洲和中国指南推荐的非精神管控类药物。全球上市多年来,替洛利生以出色的安全性和有效性而受到临床的广泛认可。替洛利生在中国的上市意味着结束了我国发作性睡病患者“超说明书”和“红处方”用药为主的困局,为我国患者提供安全、有效和便捷的治疗新选择。Pitolisant (Tiprolisant, BF-2649)是一种高亲和力的、竞争性H3受体拮抗剂,Ki为0.16 nM。同时也是组胺H3受体的反向激动剂(EC50=1.5 nM)。
TargetValue
H3 receptor
()
0.16 nM(Ki)

On the stimulation of guanosine 5′-O-(3-[ 35 S]thio)triphosphate binding to this receptor, Pitolisant (BF2.649) behaves as a competitive antagonist with a K i value of 0.16 nM and as an inverse agonist with an EC 50 value of 1.5 nM and an intrinsic activity ~50% higher than that of ciproxifan. Pitolisant displaces [ 125 I]iodoproxyfan binding from mouse brain cortical membranes with an IC 50 value of 26.4±4.5 nM. Taking into account the K d value of the radioligand (161±9 pM), the deduced K i value for Pitolisant is 14±1 nM. Pitolisant displaces [ 125 I]iodoproxyfan binding from membranes of rat glioma C6 cells stably expressing the human H 3 receptor with an IC 50 value of 4.2±0.2 nM. Taking into account the K d value of the radioligand (50±4 pM), the deduced K i value for Pitolisant is 2.7±0.5 nM. Pitolisant progressively reverses this response with a Hill coefficient close to unity and an IC 50 value of 330±68 nM, leading to a K i value of 17±4 nM. Pitolisant elicits a dose-dependent decrease of the basal-specific [ 35 S]GTPγS binding to membranes with a maximal effect corresponding to 75±1% of the basal-specific binding and an EC 50 value of 1.5±0.1 nM.

The administration of Pitolisantat a single dose of 10 mg/kg 30 min before a single dose of LY170053 (2 mg/kg b.w.) also significantly affects immobility time in the FST. Subsequent administration of the aforementioned drug sequence in mice statistically significantly increases the duration of immobility in comparison to the time determined in the control group in the FST. It decreased locomotor activity as well. In contrast, the results obtained in subchronic treatment after fifteen administrations of both drugs (Pitolisant 10 mg/kg b.w., and after 30 min LY170053 2 mg/kg b.w., and again after 4 h LY170053 2 mg/kg b.w.) show that the administration of Pitolisant followed by that of LY170053 equalized the locomotor activity in mice; in comparison to the level of motility in the control group, to which only Pitolisant is administered. More importantly, this combination of drugs significantly reduces immobility time to the level obtained in the control group in the forced swim test in mice [one-way ANOVA; F (3,20) =4.226,P=0.0181]. Rats given Pitolisant (10 mg/kg) during the conditioning phase stayed 502±94 s on the paired texture, a value not statistically different from that of controls, indicating that Pitolisant did not support place preference.

安全信息

MSDS信息

更新日期产品编号产品名称CAS号包装价格
2024/01/25HY-12199B1-[3-[3-(4-氯丙基)丙氧基]丙基]-哌啶盐酸盐
Pitolisant hydrochloride
903576-44-35mg500元
2024/01/25HY-12199B1-[3-[3-(4-氯丙基)丙氧基]丙基]-哌啶盐酸盐
Pitolisant hydrochloride
903576-44-310mM * 1mLin DMSO550元

盐酸替洛利生 上下游产品信息

"盐酸替洛利生"相关产品信息
正丙苯 二氯(3-氰基丙基)甲基硅烷 硅烷 PITOLISANT草酸盐
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 | 评选活动 | HS海关编码 | MSDS查询 | 化工站点

Copyright © 2016-2023 ChemicalBook 版权所有  京ICP备07040585号  京公海网安备11010802032676号  

互联网增值电信业务经营许可证:京ICP证150597号  互联网药品信息服务资格证编号(京)-非经营性-2015-0073  信息系统安全等级保护备案证明(三级)  营业执照公示

根据相关法律法规和本站规定,单位或个人购买相关危险物品应取得有效的资质、资格条件。
参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》《互联网危险物品信息发布管理规定》